Histiocytoses: emerging neoplasia behind inflammation

被引:152
作者
Haroche, Julien [1 ]
Cohen-Aubart, Fleur [1 ]
Rollins, Barret J. [4 ]
Donadieu, Jean [5 ]
Charlotte, Frederic [2 ]
Idbaih, Ahmed [3 ]
Vaglio, Augusto [6 ]
Abdel-Wahab, Omar [7 ]
Emile, Jean-Francois [8 ,9 ,10 ]
Amoura, Zahir [1 ]
机构
[1] Hop La Pitie Salpetriere, Serv Med Interne 2, Ctr Natl Reference Malad Auto Immunes Syst Rares, Inst E3M, F-75013 Paris, France
[2] Hop La Pitie Salpetriere, AP HP, Serv Anatomocytopathol, Paris, France
[3] Hop La Pitie Salpetriere, AP HP, Serv Neurol Mazarin, Paris, France
[4] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[5] Hop Trousseau, AP HP, Serv Hematol, Paris, France
[6] Univ Hosp, Nephrol Unit, Parma, Italy
[7] Mem Sloan Kettering Canc Ctr, Leukemia Serv, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA
[8] Ambroise Pare Hosp, AP HP, EA4340, Boulogne, France
[9] Ambroise Pare Hosp, AP HP, Dept Pathol, Boulogne, France
[10] Univ Versailles, Boulogne, France
关键词
LANGERHANS-CELL HISTIOCYTOSIS; ERDHEIM-CHESTER-DISEASE; ROSAI-DORFMAN-DISEASE; MASSIVE LYMPHADENOPATHY; SINUS HISTIOCYTOSIS; MONOCENTRIC SERIES; HIGH PREVALENCE; FOLLOW-UP; MUTATIONS; INVOLVEMENT;
D O I
10.1016/S1470-2045(17)30031-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Histiocytoses are disorders characterised by inflammation and the accumulation of cells derived from the monocyte and macrophage lineages, which results in tissue damage. Although they are often considered rare disorders with protean clinical manifestations, considerable advances in the understanding of their genetics have led to increased clinical recognition of these conditions, and fuelled further insights into their pathogenesis. In this Review, we describe insights into the cells of origin, molecular pathology, clinical features, and treatment strategies for some of the most common histiocytic disorders, including Langerhans cell histiocytosis, Erdheim-Chester disease, and Rosai-Dorfman disease. With the discovery of recurrent mutations affecting the mitogen-activated protein kinase and mTOR-AKT pathways in some of these histiocytoses, our understanding of these diseases has now evolved from the concept of a primary inflammatory condition to that of a clonal neoplastic disease. This understanding has led to the development of effective mechanism-based therapeutic strategies for patients with histiocytic diseases.
引用
收藏
页码:E113 / E125
页数:13
相关论文
共 107 条
[1]   Hematopoietic stem cell transplantation in patients with severe Langerhans cell histiocytosis and hematological dysfunction: Experience of the French Langerhans Cell Study Group [J].
Akkari, V ;
Donadieu, J ;
Piguet, C ;
Bordigoni, P ;
Michel, G ;
Blanche, S ;
Casanova, JL ;
Thomas, C ;
Vilmer, E ;
Fischer, A ;
Bertrand, Y .
BONE MARROW TRANSPLANTATION, 2003, 31 (12) :1097-1103
[2]   Erdheim-Chester disease: Case report, PCR-based analysis of clonality, and review of literature [J].
Al-Quran, S ;
Reith, J ;
Bradley, J ;
Rimsza, L .
MODERN PATHOLOGY, 2002, 15 (06) :666-672
[3]   How I treat Langerhans cell histiocytosis [J].
Allen, Carl E. ;
Ladisch, Stephan ;
McClain, Kenneth L. .
BLOOD, 2015, 126 (01) :26-35
[4]   Cell-Specific Gene Expression in Langerhans Cell Histiocytosis Lesions Reveals a Distinct Profile Compared with Epidermal Langerhans Cells [J].
Allen, Carl E. ;
Li, Liunan ;
Peters, Tricia L. ;
Leung, Hon-Chiu Eastwood ;
Yu, Alexander ;
Man, Tsz-Kwong ;
Gurusiddappa, Sivashankarappa ;
Phillips, Michelle T. ;
Hicks, M. John ;
Gaikwad, Amos ;
Merad, Miriam ;
McClain, Kenneth L. .
JOURNAL OF IMMUNOLOGY, 2010, 184 (08) :4557-4567
[5]   CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients [J].
Arnaud, Laurent ;
Hervier, Baptiste ;
Neel, Antoine ;
Hamidou, Mohamed A. ;
Kahn, Jean-Emmanuel ;
Wechsler, Bertrand ;
Perez-Pastor, Gemma ;
Blomberg, Bjorn ;
Fuzibet, Jean-Gabriel ;
Dubourguet, Francois ;
Marinho, Antonio ;
Magnette, Catherine ;
Noel, Violaine ;
Pavic, Michel ;
Casper, Jochen ;
Beucher, Anne-Berangere ;
Costedoat-Chalumeau, Nathalie ;
Aaron, Laurent ;
Salvatierra, Juan ;
Graux, Carlos ;
Cacoub, Patrice ;
Delcey, Veronique ;
Dechant, Claudia ;
Bindi, Pascal ;
Herbaut, Christiane ;
Graziani, Giorgio ;
Amoura, Zahir ;
Haroche, Julien .
BLOOD, 2011, 117 (10) :2778-2782
[6]   18F-Fluorodeoxyglucose-Positron Emission Tomography Scanning Is More Useful in Followup Than in the Initial Assessment of Patients With Erdheim-Chester Disease [J].
Arnaud, Laurent ;
Malek, Zoulikha ;
Archambaud, Frederique ;
Kas, Aurelie ;
Toledano, Dan ;
Drier, Aurelie ;
Zeitoun, Delphine ;
Cluzel, Philippe ;
Grenier, Philippe A. ;
Chiras, Jacques ;
Piette, Jean-Charles ;
Amoura, Zahir ;
Haroche, Julien .
ARTHRITIS AND RHEUMATISM, 2009, 60 (10) :3128-3138
[7]   Efficacy of the MEK inhibitor cobimetinib for wild-type BRAF Erdheim-Chester disease [J].
Aubart, Fleur Cohen ;
Emile, Jean-Francois ;
Maksud, Philippe ;
Galanaud, Damien ;
Cluzel, Philippe ;
Benameur, Neila ;
Aumaitre, Olivier ;
Amoura, Zahir ;
Haroche, Julien .
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 180 (01) :150-153
[8]   A Case of H Syndrome Showing Immunophenotye Similarities to Rosai-Dorfman Disease [J].
Avitan-Hersh, Emily ;
Mandel, Hanna ;
Indelman, Margarita ;
Bar-Joseph, Gad ;
Zlotogorski, Abraham ;
Bergman, Reuven .
AMERICAN JOURNAL OF DERMATOPATHOLOGY, 2011, 33 (01) :47-51
[9]   Recurrent BRAF mutations in Langerhans cell histiocytosis [J].
Badalian-Very, Gayane ;
Vergilio, Jo-Anne ;
Degar, Barbara A. ;
MacConaill, Laura E. ;
Brandner, Barbara ;
Calicchio, Monica L. ;
Kuo, Frank C. ;
Ligon, Azra H. ;
Stevenson, Kristen E. ;
Kehoe, Sarah M. ;
Garraway, Levi A. ;
Hahn, William C. ;
Meyerson, Matthew ;
Fleming, Mark D. ;
Rollins, Barrett J. .
BLOOD, 2010, 116 (11) :1919-1923
[10]  
BAILDAM EM, 1992, J ROY SOC MED, V85, P179